Clinical Trial Update: Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) [Phase 1, Phase 2]

View source ↗

Summary

Genmab's PRO1160 (GEN1160) Phase 1/2 trial in relapsed or refractory non-Hodgkin lymphoma has been terminated; the study also included renal cell carcinoma and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma
• Non-hodgkin Lymphoma
• Renal Cell Carcinoma

Drugs mentioned

• PRO1160 (GEN1160)

Snippet

Sponsor: Genmab | Conditions: Renal Cell Carcinoma, Nasopharyngeal Carcinoma | Phase 1, Phase 2 | Status: TERMINATED